Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Steven Rowe, MD, PhD
Radiology and Radiological Science
Johns Hopkins Medicine,
Baltimore, MD
Authored Items
Insights into the Prostate Cancer Imaging Landscape
By
Steven Rowe, MD, PhD
Videos
Interview with the Innovators
Dr Steven Rowe shares insights into the prostate cancer imaging landscape and the logistics involved with different radiotracers, with particular emphasis on PYLARIFY
®
(piflufolastat F 18).
Read More ›
Results from the OSPREY Trial in Pre-Prostatectomy Patients
By
Steven Rowe, MD, PhD
Videos
Interview with the Innovators
Dr Steven Rowe continues his discussion of PYLARIFY
®
(piflufolastat F 18) imaging, with a focus on results from the OSPREY clinical trial in pre-prostatectomy patients.
Read More ›
PYLARIFY Imaging in High-Risk Prostate Cancer
By
Steven Rowe, MD, PhD
Videos
Interview with the Innovators
Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY
®
(piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer.
Read More ›
Overview of the Molecular Characteristics of PYLARIFY
By
Steven Rowe, MD, PhD
Videos
Interview with the Innovators
Dr Steven Rowe details the molecular characteristics of PYLARIFY® (piflufolastat F 18) and the OSPREY and CONDOR pivotal trials, which led to the FDA approval of PYLARIFY®.
Read More ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Out Models Cost Patients and Employers More Than They Disclose
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors
By
Marianne Davies, DNP, ACNP, AOCNP, FAAN
;
Shawn Perkins, RN, BSN, OCN
3.
Dexamethasone-Sparing Regimen Safe and Effective in Frail Patients with Multiple Myeloma
By
William King
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes